LabGenius Therapeutics has rapidly increased its antibody discovery capabilities by expanding its EVA™ platform with advanced automation and machine learning. This upgrade now enables the company to design, produce, and test up to 2,300 complex antibody candidates within just six weeks, tripling their experimental throughput and setting a new industry benchmark.
The EVA™ platform uses a closed-loop system that combines automated functional screening with machine learning, allowing researchers to explore vast antibody design possibilities and identify high-performing molecules that traditional methods might miss. This approach significantly reduces human bias and accelerates the discovery of novel therapeutics.
Automation has streamlined hundreds of laboratory steps, from DNA synthesis to cell-based assays. By integrating over 33 devices on a single platform and leveraging technologies such as advanced liquid handlers and robotics, LabGenius maintains nearly continuous operations. Automated data processing ensures that all results are high-quality and relevant to disease models, while also minimizing errors and freeing scientists to focus on innovation.
For businesses, these advancements offer several benefits:
– Automation of repetitive lab tasks reduces costs and increases efficiency.
– Enhanced data analysis via machine learning improves predictive accuracy and decision-making.
– Parallel discovery programs enable faster development of new therapeutics and collaborations with partners.
– Improved quality control ensures reliable outcomes as scale increases.
A practical example: pharmaceutical companies can use LabGenius’s platform to rapidly screen thousands of antibody variants for cancer treatment, optimizing both efficacy and safety much faster than manual processes would allow. The system’s ability to differentiate between healthy and diseased cells based on specific markers helps overcome common challenges like off-target toxicity.
Looking forward, LabGenius aims to onboard even more sophisticated antibody formats, such as tri- and tetra-specific molecules, further expanding the therapeutic potential. As automation and AI continue to evolve, the company expects to set new standards in drug discovery speed, safety, and effectiveness.
